LIFECORE BIOMEDICAL, INC. \DE\ — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 42/100
What the filing says
Lifecore reported Q2 2026 revenues of $34.2M (down 6.2% YoY from $36.4M); six-month revenues of $57.4M (down 19.9% YoY from $71.6M). Net loss widened to $6.2M in Q2 vs. $1.1M prior year; six-month net loss $21.1M vs. $15.9M. Adjusted EBITDA declined to $8.6M (Q2) and $9.6M (six months) from $9.1M and $14.8M respectively. Company reaffirmed full-year 2026 guidance of $120–$125M revenue and $20.5–$25M Adjusted EBITDA. Added 13 new programs in past 12 months (8 late-stage); liquidity of $38.8M as of June 30.
Why this rating
Revenue down 20% YTD and net losses up 33%; however, reaffirmed guidance and pipeline growth provide offset. Relative to $223M market cap, near-term cash burn and margin compression are material but countered by stated mid-term inflection expectations. Moderate near-term headwind with strategic positioning for 2027+
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.